Optimal fosamprenavir regimen to prevent lipid abnormalities

Emanuela Lattuada; Massimiliano Lanzafame; Carmela Grosso; Fabio Soldani; Fabiana Corsini; Silvia Storato; Sandro Vento

Optimal fosamprenavir regimen to prevent lipid abnormalities

Emanuela Lattuada, Massimiliano Lanzafame, Carmela Grosso, Fabio Soldani, Fabiana Corsini, Silvia Storato, Sandro Vento

Department of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

We report our experience on the impact of different fosamprenavir boosted regimens on plasma lipid levels in 48 naïve monoinfectd- HIV-seropositive patients. Eighteen months after starting antiretroviral therapy (ART), all patients showed a good immuno-virological response, with no statistically significant differences among the three groups; no changes in ART regimens were necessary and no adverse events were reported. On the contrary, a statistically significant difference among the three groups of patients was observed in cholesterol and triglyceride levels, since higher levels of cholesterol (including LDLs) and triglycerides were observed in patients taking the higher dose of ritonavir.

Original language	English
Pages (from-to)	200-202
Number of pages	3
Journal	Acta Biomedica de l'Ateneo Parmense
Volume	80
Issue number	3
Publication status	Published - Dec 1 2009

Keywords

Cholesterol level
Fosamprenavir
Ritonavir
Triglycerides levels

ASJC Scopus subject areas

Medicine(all)

Fingerprint Dive into the research topics of 'Optimal fosamprenavir regimen to prevent lipid abnormalities'. Together they form a unique fingerprint.

Cite this

@article{ba5c19d3332d4c23bfd7db9359c3147f,

title = "Optimal fosamprenavir regimen to prevent lipid abnormalities",

abstract = "We report our experience on the impact of different fosamprenavir boosted regimens on plasma lipid levels in 48 na{\"i}ve monoinfectd- HIV-seropositive patients. Eighteen months after starting antiretroviral therapy (ART), all patients showed a good immuno-virological response, with no statistically significant differences among the three groups; no changes in ART regimens were necessary and no adverse events were reported. On the contrary, a statistically significant difference among the three groups of patients was observed in cholesterol and triglyceride levels, since higher levels of cholesterol (including LDLs) and triglycerides were observed in patients taking the higher dose of ritonavir.",

keywords = "Cholesterol level, Fosamprenavir, Ritonavir, Triglycerides levels",

author = "Emanuela Lattuada and Massimiliano Lanzafame and Carmela Grosso and Fabio Soldani and Fabiana Corsini and Silvia Storato and Sandro Vento",

year = "2009",

month = dec,

day = "1",

language = "English",

volume = "80",

pages = "200--202",

journal = "Acta Biomedica de l'Ateneo Parmense",

issn = "0392-4203",

publisher = "L'Ateneo Parmense",

number = "3",

}

TY - JOUR

T1 - Optimal fosamprenavir regimen to prevent lipid abnormalities

AU - Lattuada, Emanuela

AU - Lanzafame, Massimiliano

AU - Grosso, Carmela

AU - Soldani, Fabio

AU - Corsini, Fabiana

AU - Storato, Silvia

AU - Vento, Sandro

PY - 2009/12/1

Y1 - 2009/12/1

N2 - We report our experience on the impact of different fosamprenavir boosted regimens on plasma lipid levels in 48 naïve monoinfectd- HIV-seropositive patients. Eighteen months after starting antiretroviral therapy (ART), all patients showed a good immuno-virological response, with no statistically significant differences among the three groups; no changes in ART regimens were necessary and no adverse events were reported. On the contrary, a statistically significant difference among the three groups of patients was observed in cholesterol and triglyceride levels, since higher levels of cholesterol (including LDLs) and triglycerides were observed in patients taking the higher dose of ritonavir.

AB - We report our experience on the impact of different fosamprenavir boosted regimens on plasma lipid levels in 48 naïve monoinfectd- HIV-seropositive patients. Eighteen months after starting antiretroviral therapy (ART), all patients showed a good immuno-virological response, with no statistically significant differences among the three groups; no changes in ART regimens were necessary and no adverse events were reported. On the contrary, a statistically significant difference among the three groups of patients was observed in cholesterol and triglyceride levels, since higher levels of cholesterol (including LDLs) and triglycerides were observed in patients taking the higher dose of ritonavir.

KW - Cholesterol level

KW - Fosamprenavir

KW - Ritonavir

KW - Triglycerides levels

UR - http://www.scopus.com/inward/record.url?scp=77955899168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955899168&partnerID=8YFLogxK

M3 - Article

C2 - 20578411

AN - SCOPUS:77955899168

VL - 80

SP - 200

EP - 202

JO - Acta Biomedica de l'Ateneo Parmense

JF - Acta Biomedica de l'Ateneo Parmense

SN - 0392-4203

IS - 3

ER -